Format

Send to

Choose Destination
Curr Opin Virol. 2014 Jun;6:1-5. doi: 10.1016/j.coviro.2014.02.005. Epub 2014 Mar 15.

Progress, prospects, and problems in Epstein-Barr virus vaccine development.

Author information

1
Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, MN 55455, United States; Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN 55455, United States. Electronic address: balfo001@umn.edu.

Abstract

Epstein-Barr virus (EBV) is responsible for a farrago of acute and chronic human diseases including cancer. A prophylactic vaccine could reduce this disease burden. Several EBV vaccines have been given to humans but none has been sufficiently studied to establish safety and efficacy. EBV vaccine development has been hampered by the lack of an animal model other than subhuman primates, proprietary issues, selection of an appropriate adjuvant, and failure to reach consensus on what an EBV vaccine could or should actually achieve. A recent conference at the U.S. National Institutes of Health emphasizing the global importance of EBV vaccine and advocating a phase 3 trial to prevent infectious mononucleosis should encourage research that could eventually lead to its licensure.

PMID:
24632197
PMCID:
PMC4072744
DOI:
10.1016/j.coviro.2014.02.005
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center